Andrea B. Maier, MD PhD FRACP
MD PhD FRACP
Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, Co-Director at Centre for Healthy Longevity, National University Health System, National University of Singapore
Professor of Gerontology, Vrije Universiteit Amsterdam, The Netherlands
Andrea Maier, a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. She was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016. From 2016 to early 2021 Professor Maier served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continued her career at the National University of Singapore as Co-Director of the Centre for Healthy Longevity. Professor Maier’s research focuses on unraveling the mechanisms of ageing and age-related diseases. During the last 10 years she has conducted multiple international observational studies and intervention trials and has published more than 340 peer-reviewed articles, achieving an H index of 60, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs to disseminate aging research and an invited member of several international academic and health policy committees, including the WHO. She is the President of The Australian and New Zealand Society for Sarcopenia and Frailty Research.
Peter L.J. de Keizer, PhD
Peter L.J. de Keizer, PhD, is an associated professor “Senescence in Cancer and Aging” at the University Medical Center Utrecht and the Founder. Peter is the Founder and Managing Director of Cleara Biotech B.V., a company focused on identifying and eliminating subtypes of senescence.
Peter studied Biology/Biomolecular Science in Utrecht, The Netherlands and Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA from 1999-2004. From 2004-2009 Peter’s PhD work at the UMC Utrecht focused on FOXO and p53 transcription factors in insulin and insulin signaling, oxidative stress and DNA damage. Peter identified FOXO4 can be a pivot between senescence and apoptosis in cancer cells. Following this observation, Peter performed his Postdoctoral work as a fellow of the Dutch Cancer Society at the Buck Institute for Research on Aging in Novato, California from 2009-2012. Here, he generated the first and second generation of FOXO4 peptides to eliminate senescent and therapy-resistant cancer cells. In 2012, Peter joined the Erasmus Medical Center in Rotterdam as group leader, where he designed the third generation FOXO4-DRI peptide. This proved to be effective in counteracting signs of chemotoxicity and, excitingly, was able to restore healthspan in models for fast and natural aging, e.g. fur density, behavior and renal function. (Cell, 2017).
In January 2018, Peter started his group as an assistant professor at the UMC Utrecht, to study the mechanisms that drive senescence heterogeneity, how this individually contributes to disease development. In parallel, he founded Cleara Biotech B.V. to generate and translate 4th generation FOXO4 peptides against subtypes of senescent cells, which in 2022 are in preclinical development towards status as “investigational new drug” for malignant types of scarring-positive cancer and chronic disease.
In 2020, Peter was promoted to Associate Professor. Peter is an active advocate for cancer and aging-related societies and at political parties, healthcare providers and mainstream science events. He teaches to the lay public on aging, including primary and high schools and a range of universities. Peter is a recurring guest in general media, including 50+ items on (inter)national television, newspapers, radio and blogs, with a recent item on the BBC UK. Peter is a board member of the Dutch Society for Research on Aging (DuSRA).
Marco Demaria is an Associate Professor of Cellular Aging at the Medical Faculty of the University of Groningen, Netherlands. He obtained his PhD in Molecular Medicine at the University of Torino, Italy, under the supervision of Prof. Valeria Poli. He joined the laboratory of prof. Judith Campisi at the Buck Institute for Research on Aging, California USA, in the summer of 2010 to navigate through the complex phenotypes of senescent cells. He also started to be interested in therapeutic approaches to target the negative aspect of senescent cells. He moved to the University of Groningen and the European Research Institute for the Biology of Aging (ERIBA) in September 2015 as Group leader of the laboratory “Cellular Senescence and Age-related Pathologies”. His research is focused towards understanding the cell non-autonomous functions of senescent cells, including their roles in tissue repair, cancer and aging. The goal of his group is to dissect positive and negative roles of cellular senescence in different physiological and pathological context. His laboratory works with cellular and animal models, and collaborate with clinical departments to study senescence in human patients. The demaria laboratory is funded by several agencies, including the Dutch Research Council, the Dutch Cancer Foundation and the European Community.
Dr. Demaria published >70 peer-reviewed papers in top-tier journals. In 2021, he was ranked by Clarivate as one of the most cited scientists in the field. He is (co-)inventor of several patents related to senescence, inflammation and age-related diseases. He wrote various books and book chapters on aging and senescence. He acts as reviewer for most of the high-profile journals and serve in the editorial board of Aging Cell. He is currently the elected President of the International Cell Senescence Association. Dr Demaria has also co-founded a startup company devoted to development of senotherapies (Cleara Biotech), and serve or served as advisor for several biotech in the aging space.